IPO Prosensa Holding (RNA) is a biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Their primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. Prosensa's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy, or DMD.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment